Literature DB >> 25392256

The effect of body weight on the severity and clinical course of ulcerative colitis.

Denia Stabroth-Akil1, Ludger Leifeld, Roland Pfützer, Julia Morgenstern, Wolfgang Kruis.   

Abstract

PURPOSE: Obesity is a risk factor for inflammatory diseases such as nonalcoholic steatohepatitis, pancreatitis, and Crohn's disease. The effect of being overweight or obese on the severity and clinical course of ulcerative colitis (UC) was assessed in a retrospective analysis of data from 2000-2006.
METHODS: Two hundred and two consecutive UC patients were categorized according to body mass index (BMI). Patient and disease characteristics were compared between BMI categories using chi-square or Kruskal-Wallis tests. The percentage of patients with active UC, complications, steroid therapy, or immunosuppressive therapy was calculated for each group, and matched pair analyses were performed.
RESULTS: Ten patients (5%) were underweight, 111 (55%) were normal weight, 54 (26.7%) were overweight, and 27 (13.4%) were obese. Pancolitis was inversely related to weight. BMI was also inversely correlated to disease severity, with a significantly smaller proportion of years with chronic active disease among overweight subjects versus normal-weight subjects (17.6 versus 23.9%, p = 0.05). More overweight than normal-weight patients had no chronic active disease in any year (66 versus 49%, p = 0.06), and the proportion of years with disease complications was higher in normal weight than in overweight subjects (1.8 versus 0.4%, p = 0.08). Disease activity during 2000-2006 was higher for underweight versus normal-weight patients, and only 20% of underweight subjects had no hospital admission compared to 80% of normal-weight patients (p = 0.07).
CONCLUSIONS: This first study to explore the influence of obesity on UC showed that high BMI had rather a favorable effect on the prognosis, whereas low BMI pointed to a more severe course of the disease.

Entities:  

Mesh:

Year:  2014        PMID: 25392256     DOI: 10.1007/s00384-014-2051-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  31 in total

Review 1.  Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 2.  Systematic review: adipose tissue, obesity and gastrointestinal diseases.

Authors:  B J John; S Irukulla; A M Abulafi; D Kumar; M A Mendall
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

Review 3.  Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.

Authors:  Andreas Schäffler; Jürgen Schölmerich; Christa Büchler
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-06

4.  The impact of increased body mass index on the clinical course of Crohn's disease.

Authors:  David J Hass; Colleen M Brensinger; James D Lewis; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

Review 5.  Inflammatory bowel disease: nutritional implications and treatment.

Authors:  D B Silk; J Payne-James
Journal:  Proc Nutr Soc       Date:  1989-09       Impact factor: 6.297

6.  Body mass index and diverticular disease: a 28-year follow-up study in men.

Authors:  Anders Rosemar; Ulf Angerås; Annika Rosengren
Journal:  Dis Colon Rectum       Date:  2007-12-22       Impact factor: 4.585

Review 7.  Adipokines: inflammation and the pleiotropic role of white adipose tissue.

Authors:  Paul Trayhurn; I Stuart Wood
Journal:  Br J Nutr       Date:  2004-09       Impact factor: 3.718

8.  Transplantation of wild-type white adipose tissue normalizes metabolic, immune and inflammatory alterations in leptin-deficient ob/ob mice.

Authors:  Joseph A Sennello; Raja Fayad; Maria Pini; Melissa E Gove; Giamila Fantuzzi
Journal:  Cytokine       Date:  2007-03-26       Impact factor: 3.861

Review 9.  Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.

Authors:  E Maury; S M Brichard
Journal:  Mol Cell Endocrinol       Date:  2009-08-12       Impact factor: 4.102

Review 10.  Non-alcoholic fatty liver disease and hepatitis C infection.

Authors:  S Bondini; Z M Younossi
Journal:  Minerva Gastroenterol Dietol       Date:  2006-06
View more
  16 in total

1.  Impact of Obesity on the Management of Inflammatory Bowel Disease.

Authors:  Amanda M Johnson; Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-07

2.  Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.

Authors:  Sudeep Dhoj Thapa; Hiba Hadid; Mohammed Usman; Waseem Imam; Ahmad Hassan; Jason Schairer; Syed-Mohammed R Jafri; Nirmal Kaur
Journal:  Dig Dis Sci       Date:  2015-10-28       Impact factor: 3.199

Review 3.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

4.  Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.

Authors:  Thomas Greuter; Frédéric Porchet; Manuel B Braga-Neto; Jean-Benoit Rossel; Luc Biedermann; Philipp Schreiner; Michael Scharl; Alain M Schoepfer; Ekaterina Safroneeva; Alex Straumann; Gerhard Rogler; Stephan R Vavricka
Journal:  United European Gastroenterol J       Date:  2020-12       Impact factor: 4.623

5.  Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.

Authors:  Siddharth Singh; Nynne Nyboe Andersen; Mikael Andersson; Edward V Loftus; Tine Jess
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-29       Impact factor: 11.382

6.  Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases.

Authors:  Animesh Jain; Nghia H Nguyen; James A Proudfoot; Christopher F Martin; William J Sandborn; Michael D Kappelman; Millie D Long; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

Review 7.  Impact of Obesity on Inflammatory Bowel Disease.

Authors:  Nidah Shabbir Khakoo; Stephanie Ioannou; Nabiha Shabbir Khakoo; Shyam Vedantam; Michelle Pearlman
Journal:  Curr Gastroenterol Rep       Date:  2022-02-12

Review 8.  European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.

Authors:  Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda
Journal:  United European Gastroenterol J       Date:  2022-08-12       Impact factor: 6.866

9.  High sugar and butter (HSB) diet induces obesity and metabolic syndrome with decrease in regulatory T cells in adipose tissue of mice.

Authors:  Tatiani Uceli Maioli; Juliana Lauar Gonçalves; Mariana Camila Gonçalves Miranda; Vinícius Dantas Martins; Laila Sampaio Horta; Thais Garcias Moreira; Ana Lucia Brunialti Godard; Andrezza Fernanda Santiago; Ana Maria Caetano Faria
Journal:  Inflamm Res       Date:  2015-12-09       Impact factor: 4.575

10.  Predictors of High Health Care Utilization in Patients With Inflammatory Bowel Disease Within 1 Year of Establishing Specialist Care.

Authors:  Kenechukwu Chudy-Onwugaje; Alexander P Mamunes; David A Schwartz; Sara Horst; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.